title: Effectiveness and safety of CT-guided (125)I seed brachytherapy for postoperative locoregional recurrence in patients with non-small cell lung cancer.
abstract: To retrospectively evaluate the effectiveness and safety of CT-guided (125)I seed brachytherapy (CTISB) in 38 non-small cell lung cancer (NSCLC) patients with locoregional recurrence (LRR).
  
  
  
  In total, we analyzed 38 NSCLC patients with LRR treated with percutaneous CTISB in our hospital between 2001 and 2008; among them, 15 also received combined chemotherapy: 1-6 cycles (median, 2) of platinum-based regimens. The change in tumor volume was evaluated based on followup contrast material-enhanced CT or positron emission tomography scans.
  
  
  
  The median Day 0 dosimetry was as follows: The volume treated with the prescription dose (V100) was 96.3% (90.1-123.5%), and the minimum dose received by at least 90% of the tumor volume (D90) was 124.8 Gy (116.0-130.7 Gy). The median duration of the followup period calculated from the first CTISB treatment was 22.5 months (range, 8-98 months). Two months after CTISB, complete response, partial response, and progressive disease were observed in 50%, 37%, and 8% of patients, respectively. Median overall survival (OS) after CTISB was 21 months (95% confidence interval, 7.4-34.6), and the rates of 2-year OS, progression-free survival, and local control were 47.4%, 39.5%, and 83.5%, respectively. Both univariate and multivariate analysis indicated that D90 was significant prognostic factors for OS and progression-free survival.
  
  
  
  For selected NSCLC patients with limited LRR, CTISB is effective and can provide a high rate of local cancer control with minimal trauma.
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin, R. P. China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Huo
authors.affiliation: Department of Pain Treatment, Pain Management Center, Second Hospital of Tianjin Medical University, Tianjin, R. P. China.
authors.forename: Huixing
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin, R. P. China.
authors.forename: Jingkui
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Radiology, Second Hospital of Tianjin Medical University, Tianjin, R. P. China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin, R. P. China.
authors.forename: Weiliang
authors.initials: W
authors.lastname: Yan
authors.affiliation: Department of Oncology, Coastal People's Hospital of Tianjin, Tianjin, R. P. China.
authors.forename: Bin
authors.initials: B
authors.lastname: Huo
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin, R. P. China.
authors.forename: Guangjun
authors.initials: G
authors.lastname: Zheng
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin, R. P. China.
authors.forename: Shude
authors.initials: S
authors.lastname: Chai
authors.affiliation: Department of Radiation Oncology, Third Hospital Peking University, Beijing, R. P. China.
authors.forename: Junjie
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin, R. P. China. Electronic address: hxd_204@163.com.
authors.forename: Zhiyu
authors.initials: Z
authors.lastname: Guan
authors.affiliation: Department of Esophageal Oncology, Key Laboratory of Cancer Prevention and Therapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin, R. P. China. Electronic address: yuzhtao@hotmail.com.
authors.forename: Zhengtao
authors.initials: Z
authors.lastname: Yu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy*; D011184:Postoperative Period; D011879:Radiotherapy Dosage; D061089:Radiotherapy, Image-Guided / Q000009:adverse effects; D012189:Retrospective Studies; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
chemical_list: D007457:Iodine Radioisotopes
keywords: Brachytherapy; Iodine-125 seed; Locoregional recurrence; Non–small cell lung cancer; Surgery